Your session is about to expire
← Back to Search
Olaparib for Bladder Cancer
Study Summary
This trial is testing a new cancer drug for people with metastatic urothelial cancer. The drug is olaparib and it is given as a monotherapy (just this one drug, not in combination with any others). The objective of the study is to see what the response rate is to the drug in this population.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 3 trial • 154 Patients • NCT02184195Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- There are other specific genes (MUTYH, RECQL4, POLQ, POLE, and WRN) that may affect your eligibility for the trial.People whose cancer has spread only to their bones can participate if doctors can see the cancer on bone scans, CT or MRI. Doctors will use specific criteria to evaluate the cancer.
- Group 1: Olaparib Monotherapy
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What adverse effects have been linked to Olaparib usage?
"The safety of Olaparib was evaluated as a 2 on the risk-scale, indicating that although some evidence for its security exists, there is yet to be any proof of efficacy."
Is this a pioneering research project?
"Olaparib's journey began in 2005 with a trial sponsored by AstraZeneca, which comprised of 98 patients. Eventually this drug secured its Phase 1 approval and is currently being evaluated across 59 countries and 1468 cities, involving 188 ongoing studies."
Is there presently an opportunity for patients to partake in this research?
"Clinicaltrials.gov shows that this research is no longer actively recruiting patients, despite being initially posted on April 17th 2018 and updated as recently as July 7th 2022. However, 193 other trials are currently in need of participants."
What illnesses has Olaparib been demonstrated to be effective in treating?
"Olaparib can be an effective treatment for advance directives, ovarian cancer, and primary peritoneal carcinoma."
How many locations are currently executing this research trial?
"This research study is being conducted in various sites, including Vanderbilt-Ingram Cancer Center of Nashville, Tennessee; Johns Hopkins Sidney Kimmel Comprehensive Cancer Centre of Baltimore Maryland and Huntsman Cancer Institute University of Utah located in Salt Lake City."
Has Olaparib been explored in other scientific investigations?
"Presently, there are 27 Olaparib trials running in Phase 3 and 188 total studies for this medication. Most of the research is taking place within Houston but patients can find assistance at over 9250 other locations across the country."
How many participants have joined the trial to date?
"Patient recruitment for this trial has ceased; it debuted on April 17th 2018 and was last modified July 7th 2022. Patients may consider the 5 trials presently enrolling individuals with metastatic urothelial cancer or the 188 studies utilizing Olaparib as treatment options."
Share this study with friends
Copy Link
Messenger